This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
MYOPIC CHOROIDAL NEOVASCULARISATION
Create a future you and your patients could look forward to with EYLEA 2 mg in mCNV1
EYLEA 2 mg is indicated for adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).1
In the MYRROR study, 50% of patients treated with EYLEA 2 mg gained ≥15 letters from baseline by Week 482
MYRROR
Rapid and maintained vision gains from baseline2
Mean change in BCVA through to Week 482
Adapted from Ikuno Y, et al. 2015.
- Primary efficacy endpoint: the mean change in BCVA from baseline to Week 24 in patients with mCNV receiving EYLEA 2 mg or sham treatment2
- The primary efficacy endpoint result showed that EYLEA 2 mg-treated patients gained a mean of +12.1 letters from baseline at Week 24 compared with a letter loss of 2.0 in the sham group (treatment difference: 14.1; 95% CI: 10.8–17.4; p<0.0001)2
- At Week 48, this increased to +13.5 letters for EYLEA 2 mg-treated patients, compared with +3.9 in the sham group from baseline (treatment difference: 9.5; 95% CI: 5.4–13.7; nominal p<0.0001)2
EYLEA 2 mg was administered at baseline and when needed – if mCNV persisted or recurred at a maximum frequency of once every 4 weeks through to Week 44; n=90. The sham injection was administered at baseline, followed by repeated sham injections every 4 weeks through to Week 20 regardless of whether re-treatment criteria were fulfilled or not; this was followed by administration of EYLEA 2 mg at Week 24 and then from Week 28 to Week 44 (at a maximum frequency of once every 4 weeks) if mCNV persisted or recurred (n=31).2
- mCNV lesion size was reduced by >50% from baseline to Week 24 in the early EYLEA 2 mg treatment group (absolute reduction in lesion size was -0.24 disc areas)2
- Lesion size almost doubled in the delayed treatment group at Week 24 (absolute increase was +0.31 disc areas; nominal p<0.0001)2
- mCNV leakage was resolved by Week 48 in 86% of early EYLEA 2 mg-treated patients vs. 67% in the delayed treatment group2†
†No statistical test for difference was reported.
EYLEA 2 mg was generally well tolerated in patients with mCNV – the observed safety profile was similar to the safety profile for EYLEA 2 mg over 12 months2
- In the MYRROR study, incidences of ocular AEs were similar in both groups through Week 48 and most were assessed by investigators as mild2
The MYRROR study design2
Adapted from Ikuno Y, et al. 2015.
The overall median number of injections over the study period was 3.0 (mean 4.2). In the EYLEA 2 mg group, the median number of injections in the first 8 weeks was 2 and in quarters 2–4, it was 0.0.
‡If re-treatment criteria were fulfilled.
Abbreviations
BCVA, best corrected visual acuity. LOCF, last observation carried forward. mCNV, myopic choroidal neovascularisation. MoA, mechanism of action. PIGF, placental growth factor. RCT, randomised controlled trial. VEGF-A, vascular endothelial growth factor A. VEGF-B, vascular endothelial growth factor B.
References
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- Ikuno Y, et al. Ophthalmology 2015;22:1220–1227.
- Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
- Kanda A, et al. Sci Rep 2015;5:17946.
- Amadio M, et al. Pharmacol Res 2016;103:253–269.
- EMA. EYLEA EPAR assessment report 2012. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/eylea. Accessed: September 2024.
- Stewart M. Pharmaceuticals 2018;10:21. DOI: 10.3390/pharmaceutics10010021.
PP-EYL-GB-2339 | September 2024